Drug CategoryDrugIHD Dosing

Administration Timing Around HD Session

AntibioticsVancomycinLD 25mg/kg IV, then 500mg IV QHD (If pt weighs more than 80kg, then 750mg IV QHD)Administer Post-HD

Molecular Weight    (Da)

Excreted Unchanged (%)Normal Half-Life (Hours)ESRD Half-Life (Hours)Plasma Protein Binding (%)Volume of Distribution (L/kg)Dialytic Plasma Clearance (ml/min)% Dialyzed
144990-1004-6200-25052-600.47-1.19.6-12023-38 (high flux)


  • Alwakeel J, Najjar T, al-Yamani M, Huraib S, al-Haider A, Abu-aisha H. Comparison of the effects of three haemodialysis membranes on vancomycin disposition. International urology and nephrology 1994; 26(2), 223-8.
  • Ariano R, Fine A, Sitar D, Rexrode S, Zelenitsky S. Adequacy of a vancomycin dosing regimen in patients receiving high-flux hemodialysis. American journal of kidney diseases (the official journal of the National Kidney Foundation) 2005; 46(4), 681-7.
  • Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
  • Barth R, DeVincenzo N. Use of vancomycin in high-flux hemodialysis: experience with 130 courses of therapy. Kidney international 1996; 50(3), 929-36.
  • Bock V, Verbeelen D, Maes V, Sennesael J. Pharmacokinetics of Vancomycin in Patients Undergoing Haemodialysis and Haemofiltration. Nephrology Dialysis Transplantation 1989; 4, 635-639.
  • Brown M, Polisetty R, Gracely E, Cuhaci B, Schlecht H. Weight-based loading of vancomycin in patients on hemodialysis. Clinical infectious diseases (an official publication of the Infectious Diseases Society of America) 2011; 53(2), 164-6.
  • Böhler J, Reetze-Bonorden P, Keller E, Kramer A, Schollmeyer P. Rebound of plasma vancomycin levels after haemodialysis with highly permeable membranes. European journal of clinical pharmacology 1992; 42(6), 635-9.
  • Crawford B, Largen R, Walton T, Doran J. Once-weekly vancomycin for patients receiving high-flux hemodialysis. American journal of health-system pharmacy 2008; 65(13), 1248-53.
  • Decker B, Kays M, Chambers M, Kraus M, Moe S, Sowinski K. Vancomycin pharmacokinetics and pharmacodynamics during short daily hemodialysis. Clinical journal of the American Society of Nephrology (CJASN) 2010; 5(11), 1981-7.
  • DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL:
  • Follin S, Mueller B, Scott M, Carfagna M, Kraus M. Falsely elevated serum vancomycin concentrations in hemodialysis patients. American journal of kidney diseases (the official journal of the National Kidney Foundation) 1996; 27(1), 67-74.
  • Green K, Schulman G, Haas D, Schaffner W, D’Agata E. Vancomycin prescribing practices in hospitalized chronic hemodialysis patients. American journal of kidney diseases (the official journal of the National Kidney Foundation) 2000; 35(1), 64-8.
  • Heintz B, Matzke G, Dager W. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009; 29(5), 562-77.
  • Kawamura T, Yagi N, Sugawara H, Yamahata K, Takada M. Efficacy of Hemodialysis and the Effects of Certain Displacing Agents on Plasma Protein Binding of Sulfamethoxazole and Sulfaphenazole in Patients with Chronic Renal Failure. Chem. Pharm. Bull. 1980; 28(1), 268-76.
  • Klansuwan N, Ratanajamit C, Kasiwong S, Wangsiripaisan A. Clearance of Vancomycin during High-Efficiency Hemodialysis. Journal Med Assoc Thai 2006; 89(7), 986-991.
  • Lanese D, Alfrey P, Molitoris B. Markedly increased clearance of vancomycin during hemodialysis using polysulfone dialyzers. Kidney international 1989; 35(6), 1409-12.
  • Lucksiri A, Scott M, Mueller B, Hamburger R, Sowinski K. CAHP-210 dialyzer influence on intra-dialytic vancomycin removal. Nephrology, dialysis, transplantation (official publication of the European Dialysis and Transplant Association - European Renal Association) 2002; 17(9), 1649-54.
  • Marengo L. Sa Del Fiol F, Oliveira S et al. Vancomycin : the need to suit serum concentrations in hemodialysis patients. Brazilian Journal of Infectious Diseases 2010; 14(2), 203-208.
  • Pai A, Pai M. Vancomycin dosing in high flux hemodialysis: a limited-sampling algorithm. American journal of health-system pharmacy 2004; 61(17), 1812-6.
  • Pollard T, Lampasona V, Akkerman S et al. Vancomycin redistribution: dosing recommendations following high-flux hemodialysis. Kidney international 1994; 45(1), 232-7.
  • Quale J, Halloran J, Devincenzo N, Barth R. Removal of Vancomycin by High-Flux Hemodialysis Membranes. Antimicrobial agents and chemotherapy 1992; 36(7), 1424-7.
  • Schaedeli F, Uehlinger D. Urea kinetics and dialysis treatment time predict vancomycin elimination during high-flux hemodialysis. Clinical pharmacology and therapeutics 1998; 63(1), 26-38.
  • Scott M, Mueller B, Clark W. Vancomycin mass transfer characteristics of high-flux cellulosic dialysers. Nephrology Dialysis Transplantation 1997; 12, 2647-2653.
  • Stamatakis M, Schreiber J, Slain D, Gunel E. Vancomycin administration during dialysis with low-flux polysulfone membranes: traditional versus a supplemental dosage regimen. American journal of health-system pharmacy 2003; 60(15), 1564-8.
  • Tan C, Lee H, Ti T, Lee E. Pharmacokinetic of Intravenous Vancomycin in Patients with End-Stage Renal Failure. Therapeutic Drug Monitoring 1990; 12, 29-34.
  • Tanaka M, Orii T, Gomi T, Kobayashi H, Kanke M, Hirono S. Clinical estimation of vancomycin measurement method on hemodialysis patient. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 2002; 122(4), 269-75.
  • Touchette M, Patel R, Anandan J, Dumler F, Zarowitz, B. Vancomycin removal by high-flux polysulfone hemodialysis membranes in critically ill patients with end-stage renal disease. American journal of kidney diseases 1995; 26(3), 469-74.
  • Vandecasteele S, De Vriese A. Recent changes in vancomycin use in renal failure. Kidney international 2010; 77(9), 760-4.
  • Welage L, Mason N, Hoffman E et al. Influence of Cellulose Triacetate Hemodialyzers on Vancomycin Pharmacokinetics. Journal of American Society of Nephrology 1995; 6(4), 1284-1290.
  • Zellner D, Zellner G, Keller F. Meta-Analysis of Vancomycin pharmacokinetics. Clin. Research & Reg. Affairs 1998; 15(2), 91-113.